In response to the opioid epidemic and new guidelines, many patients on high-dose long term opioid therapy (LTOT) for chronic pain are getting tapered off opioids. As a result, a unique clinical challenge is emerging: while many on LTOT have poor pain control, functional decline, psychiatric instability, aberrancies and misuse, these issues may often worsen with opioid tapering. Currently, a clear explanation and practical guidance on how to manage this perplexing clinical scenario is lacking.
Methods
We offer a commentary with our perspective on possible mechanisms involved in this clinical phenomena and offer practical management guidance, supported by available evidence.
Results
It is not well recognized that allostatic opponent process involved in development of opioid dependence can cause worsening pain, functional status, sleep and psychiatric symptoms over time, and significant fluctuation of pain and other affective symptoms due to their bidirectional dynamic interaction with opioid dependence (‘affective dynamism’). These elements of complex persistent dependence (CPD), the grey area between simple dependence and addiction, can lead to escalating and labile opioid need, often generating aberrant behaviors. Opioid tapering, a seemingly logical intervention in this situation, may lead to worsening of pain, function and psychiatric symptoms due to development of protracted abstinence syndrome. We offer practicing clinicians management principles and practical guidance focused on management of CPD in addition to chronic pain in these difficult clinical scenarios.
Conclusion
Awareness of the science of the neuroplasticity effects of repeated use of opioids is necessary to better manage these patients with complex challenges.
Get full access to this article
View all access options for this article.
References
1.
DowellD, HaegerichTM, ChouR. CDC Guideline for Prescribing Opioids for Chronic Pain – United States, 2016. MMWR Recomm Rep. 2016;65(1):1–49.
2.
Banta-GreenCJ, MerrillJO, DoyleSR, BoudreauDM, CalsynDA. Opioid use behaviors, mental health and pain–development of a typology of chronic pain patients. Drug and alcohol dependence. 2009;104(1–2):34–42.
3.
Von KorffMR, FranklinG. Responding to America's Iatrogenic Epidemic of Prescription Opioid Addiction and Overdose. Med Care. 2016;54(5):426–429.
4.
WeimerMB, HartungDM, AhmedS, NicolaidisC. A chronic opioid therapy dose reduction policy in primary care. Substance abuse: official publication of the Association for Medical Education and Research in Substance Abuse. 2016;37(1):141–147.
5.
Weeks WB. Hailey. JAMA. 2016;316(19):1975–1976.
6.
RileyJL, WadeJB. Psychological and Demographic Factors that Modulate the Different Stages and Dimensions of Pain. In: PriceDD, BushnellMC, eds. Psychological methods of pain control: basic science and clinical perspectives. Seattle, WA: IASP Press; 2004.
7.
LeknesS, BrooksJC, WiechK, TraceyI. Pain relief as an opponent process: a psychophysical investigation. Eur J Neurosci.2008;28(4):794–801.
LeknesS, BernaC, LeeMC, SnyderGD, BieleG, TraceyI. The importance of context: when relative relief renders pain pleasant. Pain. 2013;154(3):402–410.
10.
FranklinJC, PuziaME, LeeKM, . The Nature of Pain Offset Relief in Nonsuicidal Self-Injury: A Laboratory Study. Clinical Psychological Science. 2013;1(2):110–119.
11.
NavratilovaE, MorimuraK, XieJY, AtcherleyCW, OssipovMH, PorrecaF. Positive emotions and brain reward circuits in chronic pain. J Comp Neurol.2016.
12.
ZubietaJK.Pain signal as threat and reward. Neuron. 2010;66(1):6–7.
13.
FieldsHL.Understanding how opioids contribute to reward and analgesia. Reg Anesth Pain Med. 2007;32(3):242–246.
14.
NavratilovaE, PorrecaF. Reward and motivation in pain and pain relief. Nat Neurosci.2014;17(10):1304–1312.
15.
BakerTB, TiffanyST. Morphine-Tolerance as Habituation. Psychol Rev. 1985;92(1):78–108.
16.
HoweCQ, SullivanMD. The missing ‘P’ in pain management: how the current opioid epidemic highlights the need for psychiatric services in chronic pain care. Gen Hosp Psychiatry. 2014;36(1):99–104.
17.
LeeMC, WanigasekeraV, TraceyI. Imaging opioid analgesia in the human brain and its potential relevance for understanding opioid use in chronic pain. Neuropharmacology. 2014;84:123–130.
18.
HymanSE, MalenkaRC. Addiction and the brain: the neurobiology of compulsion and its persistence. Nature reviews Neuroscience. 2001;2(10):695–703.
19.
MeyerPJ, KingCP, FerrarioCR. Motivational Processes Underlying Substance Abuse Disorder. Current topics in behavioral neurosciences. 2015.
20.
BallantyneJC, SullivanMD, KolodnyA. Opioid Dependence vs Addiction: A Distinction Without a Difference?Archives of internal medicine. 2012;172(17):1342–1343.
21.
KoobGF, Le MoalM.Review. Neurobiological mechanisms for opponent motivational processes in addiction. Philosophical transactions of the Royal Society of London Series B, Biological sciences. 2008;363(1507):3113–3123.
22.
KoobGF, StinusL, Le MoalM, BloomFE. Opponent process theory of motivation: neurobiological evidence from studies of opiate dependence. Neuroscience and biobehavioral reviews. 1989;13(2–3):135–140.
23.
Le MoalM, KoobGF. Drug addiction: pathways to the disease and pathophysiological perspectives. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology. 2007;17(6–7):377–393.
24.
BallantyneJC.Assessing the prevalence of opioid misuse, abuse, and addiction in chronic pain. Pain. 2015;156(4):567–568.
25.
DowellD, HaegerichTM, ChouR. CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016. MMWR Recommendations and Reports. 2016;65(1):1–49.
26.
LembkeA.Why doctors prescribe opioids to known opioid abusers. The New England journal of medicine. 2012;367(17):1580–1581.
27.
EisenbergE, SuzanE, PudD. Opioid-induced hyperalgesia (OIH): a real clinical problem or just an experimental phenomenon?J Pain Symptom Manage. 2015;49(3):632–636.
28.
YiP, PryzbylkowskiP. Opioid Induced Hyperalgesia. Pain medicine (Malden, Mass). 2015;16Suppl1:S32–36.
29.
BespalovA, MullerR, ReloAL, HudzikT. Drug Tolerance: A Known Unknown in Translational Neuroscience. Trends in pharmacological sciences. 2016.
30.
BallantyneJC, ShinNS. Efficacy of opioids for chronic pain: a review of the evidence. The Clinical journal of pain. 2008;24(6):469–478.
31.
RaffaRB, PergolizziJVJr.Opioid-induced hyperalgesia: is it clinically relevant for the treatment of pain patients?Pain Manag Nurs. 2013;14(3):e67–83.
32.
VolkowND, McLellanAT. Opioid Abuse in Chronic Pain–Misconceptions and Mitigation Strategies. The New England journal of medicine. 2016;374(13):1253–1263.
33.
MiguezG, LabordaMA, MillerRR. Classical conditioning and pain: conditioned analgesia and hyperalgesia. Acta Psychol (Amst). 2014;145:10–20.
34.
KalantH.Research on tolerance: What can we learn from history?Alcoholism-Clinical and Experimental Research. 1998;22(1):67–76.
35.
SatelSL, KostenTR, SchuckitMA, FischmanMW. Should protracted withdrawal from drugs be included in DSM-IV?The American journal of psychiatry. 1993;150(5):695–704.
36.
HeiligM, EgliM, CrabbeJC, BeckerHC. Acute withdrawal, protracted abstinence and negative affect in alcoholism: are they linked?Addiction biology. 2010;15(2):169–184.
37.
SolomonRL.The opponent-process theory of acquired motivation: the costs of pleasure and the benefits of pain. Am Psychol.1980;35(8):691–712.
38.
ShurmanJ, KoobGF, GutsteinHB. Opioids, Pain, the Brain, and Hyperkatifeia: A Framework for the Rational Use of Opioids for Pain. Pain Medicine. 2010;11(7):1092–1098.
39.
WhiteJM.Pleasure into pain: the consequences of long-term opioid use. Addictive behaviors. 2004;29(7):1311–1324.
KerteszSG.Turning the tide or riptide? The changing opioid epidemic. Substance abuse: official publication of the Association for Medical Education and Research in Substance Abuse. 2017;38(1):3–8.
45.
BerlandDW, MalinoffHL, WeinerMA, PrzybylskiR. When Opioids Fail in Chronic Pain Management: The Role for Buprenorphine and Hospitalization. American Journal of Therapeutics. 2013;20(4):316–321.
46.
ButlerS.Buprenorphine—Clinically useful but often misunderstood. Scandinavian Journal of Pain. 2013;4(3):148–152.
RhodinA, GronbladhL, NilssonLH, GordhT. Methadone treatment of chronic non-malignant pain and opioid dependence–a long-term follow-up. Eur J Pain. 2006;10(3):271–278.
50.
NeumannAM, BlondellRD, JaanimagiU, . A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction. J Addict Dis.2013;32(1):68–78.
51.
HeitHA, CovingtonE, GoodPM. Dear DEA. Pain medicine (Malden, Mass). 2004;5(3):303–308.
52.
Center for Substance Abuse T. SAMHSA/CSAT Treatment Improvement Protocols.Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2004.
53.
VA/DoD Clinical Practive Guideleine Management of Opioid Therapy for Chronic pain. The Management of Opioid Therapy for Chronic Pain Working Group;2010.
54.
BlondellRD, AshrafiounL, DambraCM, FoschioEM, ZielinskiAL, SalcedoDM. A Clinical Trial Comparing Tapering Doses of Buprenorphine with Steady Doses for Chronic Pain and Co-existent Opioid Addiction. Journal of addiction medicine. 2010;4(3):140–146.
55.
BernaC, KulichRJ, RathmellJP. Tapering Long-term Opioid Therapy in Chronic Noncancer Pain: Evidence and Recommendations for Everyday Practice. Mayo Clin Proc. 2015;90(6):828–842.
